Blue Earth Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BLUE EARTH
BLUE EARTH has two approved drugs.
There are fourteen US patents protecting BLUE EARTH drugs.
There are one hundred and seven patent family members on BLUE EARTH drugs in twenty-four countries.
Summary for Blue Earth
| International Patents: | 107 |
| US Patents: | 14 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Blue Earth
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | 12,377,176 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | 11,413,360 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | 12,036,290 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Blue Earth | AXUMIN | fluciclovine f-18 | SOLUTION;INTRAVENOUS | 208054-001 | May 27, 2016 | RX | Yes | Yes | 10,933,147 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | 12,357,711 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | 12,427,207 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Blue Earth | AXUMIN | fluciclovine f-18 | SOLUTION;INTRAVENOUS | 208054-001 | May 27, 2016 | RX | Yes | Yes | 9,387,266 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Blue Earth
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Blue Earth | AXUMIN | fluciclovine f-18 | SOLUTION;INTRAVENOUS | 208054-001 | May 27, 2016 | 5,808,146 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Blue Earth Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 4424378 | ⤷ Start Trial |
| Portugal | 3917626 | ⤷ Start Trial |
| South Korea | 20140108350 | ⤷ Start Trial |
| Israel | 235029 | ⤷ Start Trial |
| Japan | 5635225 | ⤷ Start Trial |
| Hungary | E070098 | ⤷ Start Trial |
| South Korea | 20080071146 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
